OPEN END-TURBO-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 20:35:19 28/06/2024 BST | ||
| 2.23 EUR | -0.89% |
|
| Current month | +10.24% | ||
| 1 month | +14.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 2.26 | +0.44% |
| 27/06/24 | 2.25 | 0.00% |
| 26/06/24 | 2.25 | +0.90% |
| 25/06/24 | 2.23 | -1.33% |
| 24/06/24 | 2.26 | +2.26% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 08:35 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | HSBC |
| WKN | TT9R3L |
| ISIN | DE000TT9R3L7 |
| Date issued | 03/12/2021 |
| Strike | 234.3 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.35 € |
|---|---|
| Lowest since issue | 0.08 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
